Intravenous nicardipine and labetalol use in hypertensive patients with signs or symptoms suggestive of end-organ damage in the emergency department: a subgroup analysis of the CLUE trial

Posted at — Mario Hernández Cueto — junio 11th, 2013 — 9:43 under investigaciones

Intravenous nicardipine and labetalol use in hypertensive patients with signs or symptoms suggestive of end-organ damage in the emergency department: a subgroup analysis of the CLUE trial

InvestigacionesPor: Chad M Cannon, Phillip Levy, Brigitte M Baumann, Pierre Borczuk, Abhinav Chandra, David M Cline, Deborah B Diercks, Brian Hiestand, Amy Hsu, Preeti Jois, Brian Kaminski, Richard M Nowak, Jon W Schrock, Joseph Varon y W Frank Peacock.    BMJ Open 2013;3:e002338 doi.

To compare the efficacy of Food and Drug Administration recommended dosing of nicardipine versus labetalol for the management of hypertensive patients with signs and/or symptoms (S/S) suggestive of end-organ damage (EOD). Design Secondary analysis of the multicentre prospective, randomised CLUE trial. In the setting of hypertension with suspected EOD, patients treated with nicardipine are more likely to reach prespecified SBP targets within 30 min than patients receiving labetalol. [Actualizado: 11 de junio de 2013].

No responses yet